Last update Aug. 3, 2022
It is a recombinant form of human interleukin-1 receptor antagonist (IL-1Ra) used, alone or associated with methotrexate, in the treatment of rheumatoid arthritis, neonatal-onset multisystem inflammatory disease and deficiency of interleukin-1 receptor antagonist. Subcutaneous administration once daily.
Since the last update we have not found published data on its excretion in breastmilk.
Being a polypeptide of 153 amino acids with a large molecular weight, it is very unlikely to pass into breast milk.
Its low oral bioavailability makes it difficult for it to pass to the infant’s plasma via ingested breast milk as, due to its protein nature, it degrades in the gastrointestinal tract and is not absorbed.
No problems have been observed in infants of mothers treated with anakinra. (Duman 2019, Smith 2018, Youngstein 2017, Chang 2014, Berger 2009)
Expert authors consider the use of this medication compatible with breastfeeding if no other options are available. (Hale, LactMed, Sammaritano 2020, Götestam 2016, Briggs 2015, Grunewald 2015, Witzel 2014)
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2006 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM